Inhibiting UHRF1 expression enhances radiosensitivity in human esophageal squamous cell carcinoma

Molecular Biology Reports

Volumn 40, Issue 9, 2013, Pages 5225-5235

  Yang, Congrong ^a   Wang, Yadi ^a   Zhang, Fuli ^b   Sun, Guogui ^c   Li, Chenglin ^a   Jing, Shaowu ^a   Liu, Qing ^a   Cheng, Yunjie ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c People's Hospital of Tangshan   (China)

Author keywords

Esophageal squamous cell carcinoma; Lentivirus mediated shRNA; Radiosensitivity; UHRF1

Indexed keywords

CELL PROTEIN; HISTONE H2AX; KU ANTIGEN; KU80 ANTIGEN; NUCLEAR PROTEIN; PROTEIN GAMMAH2AX; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAIN 1; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER TISSUE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY;

LENTIVIRUS;

ANALYSIS OF VARIANCE; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; OLIGONUCLEOTIDES; RADIATION TOLERANCE; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY;

EID: 84883298525     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2559-6     Document Type: Article

References (47)

1. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-2252
2. Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics. CA Cancer J Clin 55:74-108
3. Borghesi S, Hawkins MA, Tait D (2008) Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol 20:221-226
4. Hopfner R, Mousli M, Jeltsch JM et al (2000) ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res 60:121-128
5. Muto M, Utsuyama M, Horiguchi T et al (1995) The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines. Cell Prolif 28:645-657
6. Hashimoto H, Horton JR, Zhang X et al (2009) UHRF1, a modular multi-domain protein, regulates replication-coupled crosstalk between DNA methylation and histone modifications. Epigenetics 4:8-14
7. Karagianni P, Amazit L, Qin J et al (2008) ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol 28:705-717
8. Jeanblanc M, Mousli M, Hopfner R et al (2005) The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24:7337-7345
9. Bostick M, Kim JK, Esteve PO et al (2007) UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317:1760-1764
10. Avvakumov GV, Walker JR, Xue S et al (2008) Structural basis for recognition of hemimethylated DNA by the SRA domain of human UHRF1. Nature 455:822-825
11. Hashimoto H, Horton JR, Zhang X et al (2008) The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 455:826-829
12. Arita K, Ariyoshi M, Tochio H et al (2008) Recognition of hemimethylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 455:818-821
13. Unoki M, Nishidate T, Nakamura Y (2004) ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23:7601-7610
14. Citterio E, Papait R, Nicassio F et al (2004) Np95 is a histone-binding protein endowed with ubiquitin ligase activity. Mol Cell Biol 24:2526-2535
15. Jenkins Y, Markovtsov V, Lang W et al (2005) Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16:5621-5629
16. Sharif J, Muto M, Takebayashi S et al (2007) The SRA protein Np95 mediates epigenetic inheritance by recruiting DNMT1 to methylated DNA. Nature 450:908-912
17. Kim JK, Esteve PO, Jacobsen SE et al (2009) UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 37:493-505
18. Achour M, Jacq X, Ronde P et al (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27:2187-2197
19. Arima Y, Hirota T, Bronner C et al (2004) Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9:131-142
20. Alhosin M, Abusnina A, Achour M et al (2010) Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 79:1251-1260
21. Bronner C, Fuhrmann G, Chédin Fl et al (2009) UHRF1 links the histone code and DNA methylation to ensure faithful epigenetic memory inheritance. Genet Epigenet 2:29-36
22. Bronner C, Chataigneau T, Schini-Kerth VB et al (2007) The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory. Curr Med Chem 14:2629-2641
23. Hopfner R, Mousli M, Oudet P et al (2002) Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase IIα expression. Anticancer Res 22:3165-3170
24. Bronner C, Hopfner R, Mousli M (2002) Transcriptional regulation of the topoisomerase II alpha gene. Anticancer Res 22:605-612
25. Bronner C, Achour A, Arima Y et al (2007) The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther 115:419-434
26. Unoki M, Brunet J, Mousli M (2009) Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 78:279-288
27. Lorenzato M, Caudroy S, Bronner C et al (2005) Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol 36:1101-1107
28. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V et al (2005) Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129:1454-1463
29. Unoki M, Kelly JD, Neal DE et al (2009) UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 101:98-105
30. Unoki M, Daigo Y, Koinuma J et al (2012) UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 103:217-222
31. Daskalos A, Oleksiewicz U, Filia A et al (2011) UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer 117:1027-1037
32. Muto M, Kanari Y, Kubo E et al (2002) Targeted disruption of NP95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks. J Biol Chem 277:34549-34555
33. Sun Y (2003) Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2:623-629
34. Un F, Oi C, Prosser M, Wang N et al (2006) Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity. Anticancer Res 26:2761-2767
35. Li XL, Meng QH, Fan SJ (2009) Adenovirus-mediated expression of UHRF1 reduces the radiosensitivity of cervical cancer HeLa cells to gamma-irradiation. Acta Pharmacol Sin 30:458-466
36. Li XL, Meng QH, Rosen EM et al (2011) UHRF1 confers radioresistance to human breast cancer cells. Int J Radiat Biol 87:263-273
37. Kihara C, Seki T, Furukawa Y et al (2000) Mutations in Zinc-binding domains of p53 as a prognostic marker of esophageal cancer patients. Cancer Res 91:190-198
38. Casson AG, Tammemagi M, Eskandarian S et al (1998) p53 alterations in esophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol 51:71-79
39. Wang Q, Fan S, Eastman A et al (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965
40. Suganuma M, Kawabe T, Hori H et al (1999) Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res 59:5887-5891
41. Tomamoto T, Ohnishi K, Takahashi A et al (1999) Correlation between γ-ray-induced G2 arrest and radioresistance in two human cancer cells. Int J Radiat Oncol Biol Phys 44:905-909
42. Olive PL, Durand RE (1997) Apoptosis: an indicator of radiosensitivity in vitro? Int J Radiat Biol 71:695-707
43. Dubray B, Breton C, Delic J et al (1997) In vitro radiation-induced apoptosis and tumour response to radiotherapy: a prospective study in patients with non-Hodgkin lymphomas treated by low-dose irradiation. Int J Radiat Biol 72:759-760
44. Aldridge DR, Radford IR (1998) Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines. Cancer Res 58:2817-2824
45. Sirzen F, Zhivotovsky B, Nilsson A et al (1998) Higher spontaneous apoptotic index in smallcell compared with non-small-cell lung carcinoma cell lines: lack of correlation with Bcl-2/Bax. Lung Cancer 22:1-13
46. Shrivastav M, De Haro LP, Nickoloff JA (2008) Regulation of DNA double-strand break repair pathway choice. Cell Res 18:134-147
47. Mladenov E, Iliakis G (2011) Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat Res 7:61-72